nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

18.12.2017 | Review – Clinical Oncology

Cardiovascular effects of Hodgkin’s lymphoma: a review of literature

verfasst von: Aasems Jacob, Bragadheeswar Thyagarajan, Monisha Priyadarshini Kumar, Nasreen Shaikh, David Sharon

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Hodgkin’s lymphoma (HL) constitutes 0.6% of all the cancers diagnosed worldwide and 10% of all lymphomas. Ten-year survival rate for HL is estimated to be 80% and cardiovascular death is the prevalent cause for a non-malignant death among these HL survivors. We are reviewing the cardiovascular morbidities associated with Hodgkin’s lymphoma from the available literature. We performed a systematic review of all articles published from January 1, 1960 to October 1, 2016 on the MEDLINE database using PubMed search engine. Key factors in the diagnosis and management of these conditions are discussed in individual sections.

Adams MJ, Lipsitz SR, Colan SD et al (2004) Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22:3139CrossRefPubMed

Adler Y, Charron P, Imazio M et al (2015) European Society of Cardiology (ESC) 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36(42):2921–2964CrossRefPubMed

Akhter MW, Aronson D, Bitar F, Khan S, Singh H et al (2004) Effect of elevated admission serum creatinine and its worsening on outcome in hospitalised patients with decompensated heart failure. Am J Cardiol 94:957–960CrossRefPubMed

Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al (2003) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21:3431–3439CrossRefPubMed

Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109(5):1878–1886CrossRefPubMed

Al-Kindi SG, Abu-Zeinah GF, Kim CH, Hejjaji V, William BM, Caimi PF, Oliveira GH (2015) Trends and disparities in cardiovascular mortality among survivors of Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 15(12):748–752CrossRefPubMed

Armenian SH, Xu L, Ky B et al (2016) Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 34:1122–1130CrossRefPubMed

Armenian SH, Lacchetti C, Barac A et al (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35(8):893–911. https://doi.org/10.1200/JCO.2016.70.5400 CrossRefPubMed

Bashir H, Hudson MM, Kaste SC, Howard SC, Krasin M, Metzger ML (2007) Pericardial involvement at diagnosis in pediatric Hodgkin lymphoma patients. Pediatr Blood Cancer 49(5):666–671CrossRefPubMed

Bilora F, Veronese F, Zancan A, Biasiolo M, Pomerri F, Muzzio PC (2010) Autonomic dysfunction in Hodgkin and non-Hodgkin lymphoma. A paraneoplastic syndrome? Hematol Rep 2(1):e8. https://doi.org/10.4081/hr.2010.e8 CrossRefPubMedPubMedCentral

Birgegård G (2008) Managing anemia in lymphoma and multiple myeloma. Ther Clin Risk Manag 4(2):527–539CrossRefPubMedPubMedCentral

Bosch X, Rovira M, Sitges M et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies). J Am Coll Cardiol 61:2355–2362CrossRefPubMed

Brand MD, Abadi CA, Aurigemma GP, Dauerman HL, Meyer TE (2001) Radiation-associated valvular heart disease in Hodgkin’s disease is associated with characteristic thickening and fibrosis of the aortic-mitral curtain. J Heart Valve Dis 10(5):681–685PubMed

Cagdas M, Velibey Y, Calik AN, Satilmis S (2012) An incidentally detected paraaortic mass diagnosed as bulky disease. Turk Kardiyol Dern Ars 40(2):197CrossRefPubMed

Cavill I, Auerbach M, Bailie GR, Barrett-Lee P, Beguin Y, Kaltwasser P, Littlewood T, Macdougall IC, Wilson K (2006) Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin 22(4):731–737CrossRefPubMed

Cella L, Liuzzi R, Conson M et al (2011) Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin’s lymphoma. Radiother Oncol 101(2):316–321CrossRefPubMed

Chen AB, Punglia RS, Kuntz KM et al (2009) Cost effectiveness and screening interval of lipid screening in Hodgkin’s lymphoma survivors. J Clin Oncol 27:5383CrossRefPubMedPubMedCentral

Chiles C, Woodard PK, Gutierrez FR, Link KM (2001) Metastatic involvement of the heart and pericardium: CT and MR imaging. Radiographics 21:439–449CrossRefPubMed

Crowe JE (1975) Cardiophrenic adenopathy in Hodgkin disease. Am J Dis Child 129(1):116–117PubMed

Cutter DJ, Schaapveld M, Darby SC et al (2015) Risk for valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv008 PubMedPubMedCentral

Dawson WB, Mayo JR, Muller NL (1990) Computed tomography of cardiac and pericardial tumors. Can Assoc Radiol J 41:270–275PubMed

De Bruin ML, Dorresteijn LD, van’t Veer MB et al (2009) Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 101:928CrossRefPubMed

Diehl LF, Hopper KD, Giguere J, Granger E, Lesar M (1991) The pattern of intrathoracic Hodgkin’s disease assessed by computed tomography. J Clin Oncol 9:438–443CrossRefPubMed

Diehl V, Thomas RK, Re D (2004) Part II: Hodgkin’s lymphoma—diagnosis and treatment. Lancet Oncol 5:19–26CrossRefPubMed

Dubrey SW, Hawkins PN, Falk RH (2011) Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart [British Cardiac Society] 97(1):75–84CrossRef

Engert A, Josting A, Haverkamp H et al (2010) Epoetin alfa in patients with advanced-stage Hodgkin’s lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 28(13):2239–2245CrossRefPubMed

Ewing DJ, Martyn CN, Young RJ et al (1985) The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 8:491–498CrossRefPubMed

Georgakopoulos P, Roussou P, Matsakas E et al (2010) Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 2010 85:894CrossRefPubMed

Groarke JD, Tanguturi VK, Hainer J et al (2015) Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. J Am Coll Cardiol 65:573CrossRefPubMed

Gulati G, Heck SL, Ree AH et al (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671CrossRefPubMedPubMedCentral

Hadar A, Sheiner E, Press F, Katz A, Katz M (2004) Dilated cardiomyopathy in a pregnant woman after doxorubicin and radiotherapy for Hodgkin’s disease: a case report. J Reprod Med 49(5):401–403PubMed

Hajra A, Bandyopadhyay D, Layek M, Mukhopadhyay S (2015) Cardiac tamponade as initial presentation of Hodgkin lymphoma. J Clin Imaging Sci 5:67CrossRefPubMedPubMedCentral

Hancock SL, Hoppe RT (1996) Long-term complications of treatment and causes of mortality after Hodgkin’s disease. Semin Radiat Oncol 6:225–242CrossRefPubMed

Hasan S, Dinh K, Lombardo F et al (2004) Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc 96(2):196–199PubMedPubMedCentral

Heidenreich PA, Hancock SL, Vagelos RH et al (2005) Diastolic dysfunction after mediastinal irradiation. Am Heart J 150:977CrossRefPubMed

Heidenreich PA, Schnittger I, Strauss HW et al (2007) Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol 25:43CrossRefPubMed

Hering D, Faber L, Horstkotte D (2003) Echocardiographic features of radiation-associated valvular disease. Am J Cardiol 92(2):226–230CrossRefPubMed

Janeczek M, Bąkała W (2012) Acquired pulmonary stenosis due to Hodgkin’s lymphoma. Kardiol Pol 70(5):527–528 (Polish)PubMed

Kalay N, Basar E, Ozdogru I et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258CrossRefPubMed

Kaya MG, Ozkan M, Gunebakmaz O et al (2013) Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 167:2306CrossRefPubMed

Keelan MH Jr, Rudders RA (1974) Successful treatment of radiation pericarditis with corticosteroids. Arch Intern Med 134(1):145–147CrossRefPubMed

Korecki J, Kamiński KA, Lisowska A, Musiał WJ (2005) Supraventricular tachycardia and pulmonary hypertension at the presentation of Hodgkin’s disease. Acta Cardiol 60(6):655–657CrossRefPubMed

Larsen RL, Jakacki RI, Vetter VL et al (1992) Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 70:73CrossRefPubMed

Larsson O, Stein G, Seivers J (1976) Hodgkin’s disease presenting as pericarditis. Med J Aust 2(7):254–255PubMed

Lipshultz SE, Rifai N, Dalton VM et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145–153CrossRefPubMed

Lotrionte M, Palazzoni G, Abbate A et al (2013) Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (liposomal doxorubicin–investigational chemotherapy–tissue doppler imaging evaluation) randomized pilot study. Int J Cardiol 167:1055–1057CrossRefPubMed

Machann W, Beer M, Breunig M et al (2010) Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 79(4):1117–1123CrossRefPubMed

Maher EA, Shepherd FA, Todd TJ (1996) Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 112:637–643CrossRefPubMed

Maraldo MV, Aznar MC, Vogelius IR, Petersen PM, Specht L (2013) Involved node radiation therapy: an effective alternative in early-stage Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 85(4):1057–1065CrossRefPubMed

Marks RD Jr, Agarwal SK, Constable WC (1973) Radiation induced pericarditis in Hodgkin’s disease. Acta Radiol Ther Phys Biol 12(4):305 – 12CrossRefPubMed

Meng Q, Lai H, Lima J et al (2002) Echocardiographic and pathological characteristics of cardiac metastasis in patients with lymphoma. Oncol Rep 9:85–88PubMed

Millaire A, Wurtz A de GP et al (1992) Malignant pericardial effusions: usefulness of pericardioscopy. Am Heart J 124:1030–1034CrossRefPubMed

Ng AK, Bernardo MP, Weller E et al (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 20:2101–2108CrossRefPubMed

Petersen CD, Robinson WA, Kurnick JE (1976) Involvement of the heart and pericardium in the malignant lymphomas. Am J Med Sci 272:161–165CrossRefPubMed

Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808–3815CrossRefPubMed

Rizzo JD, Brouwers M, Hurley P et al (2010) American Society of Clinical Oncology; American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28(33):4996–5010CrossRefPubMed

Roberts WC, Glancy DL, DeVita VT Jr (1968) Heart in malignant lymphoma [Hodgkin’s disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides]. A study of 196 autopsy cases. Am J Cardiol 22:85–107CrossRefPubMed

Ruhl U, Albrecht M, Dieckmann K et al (2001) Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 51:1209–1218CrossRefPubMed

Santoro A, Bonadonna G, Valagussa P et al (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27CrossRefPubMed

Schachter S, Freeman R (1982) Transient ischemic attack and adriamycin cardiomyopathy. Neurology 32(12):1380–1381CrossRefPubMed

Schoen FJ, Berger BM, Guerina NG (1984) Cardiac effects of noncardiac neoplasms. Cardiol Clin 2:657–670PubMed

Serrano C, Cortés J, De Mattos-Arruda L et al (2012) Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 23:897–902CrossRefPubMed

Shepherd FA (1997) Malignant pericardial effusion. Curr Opin Oncol 9:170–174CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332 CrossRefPubMed

Specht L, Yahalom J, Illidge T et al (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862CrossRefPubMed

Steinherz LJ (1997) Anthracycline-induced cardiotoxicity. Ann Intern Med 126:827–828CrossRefPubMed

Swerdlow AJ, Higgins CD, Smith P et al (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99(3):206–214CrossRefPubMed

Talreja DR, Edwards WD, Danielson GK et al (2003) Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. Circulation 108:1852CrossRefPubMed

Tirelli U, Errante D, Van Glabbeke M et al (1998) CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin’s lymphoma. results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16(1):27–34CrossRefPubMed

Turner ML, Boland OM, Parker AC, Ewing DJ (1993) Subclinical autonomic dysfunction in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol 84(4):623–626CrossRefPubMed

van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM, van Leeuwen FE (2015) Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175(6):1007–1017CrossRefPubMed

van Dalen EC, van der Pal HJ, Kremer LC (2016) Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev 3:CD005008PubMed

van Nimwegen FA, Schaapveld M, Cutter DJ et al (2016) Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 34:235–243CrossRefPubMed

Varat MA, Adolph RJ, Fowler NO (1972) Cardiovascular effects of anemia. Am Heart J 83:415–426CrossRefPubMed

Veinot JP, Edwards WD (1996) Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 27:766–773CrossRefPubMed

Virk SA, Chandrakumar D, Villanueva C, Wolfenden H, Liou K, Cao C (2015) Systematic review of percutaneous interventions for malignant pericardial effusion. Heart 101(20):1619–1626. https://doi.org/10.1136/heartjnl-2015-307907 (Review)CrossRefPubMed

Xiros N, Binder T, Anger B, Böhlke J, Heimpel H (1988) Idiopathic thrombocytopenic purpura and Autoimmune hemolytic anemia in Hodgkin’s disease. Eur J Haematol 40:437–441CrossRefPubMed

Zubrikhina GN, Blindar VN, Matveeva II, Demina EA (2015) The characteristics of anemic syndrome in patients with prevalent phases of Hodgkin lymphoma before treatment. Klin Lab Diagn 60(2):28–32 (Russian)PubMed

Titel: Cardiovascular effects of Hodgkin’s lymphoma: a review of literature
verfasst von: Aasems Jacob
Bragadheeswar Thyagarajan
Monisha Priyadarshini Kumar
Nasreen Shaikh
David Sharon
Publikationsdatum: 18.12.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-017-2560-x

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Cardiovascular effects of Hodgkin’s lymphoma: a review of literature

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16

Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression

A novel biopsy-related parameter derived from location and relationship of positive cores on standard 12-core trans-rectal ultrasound-guided prostate biopsy: a useful parameter for predicting tumor volume compared to number of positive cores

Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade

The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer

A revision of the Tokuhashi revised score improves the prognostic ability in patients with metastatic spinal cord compression

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie